

Alexander Hein

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8426589/publications.pdf>

Version: 2024-02-01

160
papers

11,432
citations

71004

43
h-index

39744

98
g-index

174
all docs

174
docs citations

174
times ranked

20609
citing authors

#	ARTICLE	IF	CITATIONS
1	Maternal SARS-CoV-2 infection during pregnancy: possible impact on the infant. <i>European Journal of Pediatrics</i> , 2022, 181, 413-418.	1.3	14
2	Pregnant and Postpartum Women Requiring Intensive Care Treatment for COVID-19 – First Data from the CRONOS-Registry. <i>Journal of Clinical Medicine</i> , 2022, 11, 701.	1.0	24
3	OUP accepted manuscript. <i>Human Molecular Genetics</i> , 2022, , .	1.4	1
4	Prevalence of SARS-CoV-2 in Pregnant Women Assessed by RT-PCR in Franconia, Germany: First Results of the SCENARIO Study (SARS-CoV-2 prevalence in pregnancy and at birth in Franconia). <i>Geburtshilfe Und Frauenheilkunde</i> , 2022, 82, 226-234.	0.8	6
5	Decision Conflicts in Clinical Care during COVID-19: A Patient Perspective. <i>Healthcare (Switzerland)</i> , 2022, 10, 1019.	1.0	5
6	Occurrence and characteristics of patients with de novo advanced breast cancer according to patient and tumor characteristics – A retrospective analysis of a real world registry. <i>European Journal of Cancer</i> , 2022, 172, 13-21.	1.3	1
7	Identification of Two Genetic Loci Associated with Leukopenia after Chemotherapy in Patients with Breast Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 3342-3355.	3.2	3
8	Cross-Cancer Genome-Wide Association Study of Endometrial Cancer and Epithelial Ovarian Cancer Identifies Genetic Risk Regions Associated with Risk of Both Cancers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 217-228.	1.1	12
9	Influence of Family History of Breast or Ovarian Cancer on Pathological Complete Response and Long-Term Prognosis in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy. <i>Breast Care</i> , 2021, 16, 254-262.	0.8	0
10	Mendelian randomization analyses suggest a role for cholesterol in the development of endometrial cancer. <i>International Journal of Cancer</i> , 2021, 148, 307-319.	2.3	35
11	Analysis of Oncological Second Opinions in a Certified University Breast and Gynecological Cancer Center Regarding Consensus between the First and Second Opinion and Conformity with the Guidelines. <i>Breast Care</i> , 2021, 16, 291-298.	0.8	2
12	Odontoblast TRPC5 channels signal cold pain in teeth. <i>Science Advances</i> , 2021, 7, .	4.7	42
13	Association of genomic variants at <i>PAX8</i> and <i>PBX2</i> with cervical cancer risk. <i>International Journal of Cancer</i> , 2021, 149, 893-900.	2.3	7
14	Identification and validation of expressed HLA-binding breast cancer neoepitopes for potential use in individualized cancer therapy. , 2021, 9, e002605.		7
15	Genetic analyses of gynecological disease identify genetic relationships between uterine fibroids and endometrial cancer, and a novel endometrial cancer genetic risk region at the WNT4 1p36.12 locus. <i>Human Genetics</i> , 2021, 140, 1353-1365.	1.8	18
16	Comprehensive characterization of endometriosis patients and disease patterns in a large clinical cohort. <i>Archives of Gynecology and Obstetrics</i> , 2021, , 1.	0.8	2
17	Prognostic effect of low-level HER2 expression in patients with clinically negative HER2 status. <i>European Journal of Cancer</i> , 2021, 155, 1-12.	1.3	39
18	Dendritic cell-based immunotherapy (DCVAC/OvCa) combined with second-line chemotherapy in platinum-sensitive ovarian cancer (SOV02): A randomized, open-label, phase 2 trial. <i>Gynecologic Oncology</i> , 2021, 162, 652-660.	0.6	17

#	ARTICLE	IF	CITATIONS
19	Mammographic density and prognosis in primary breast cancer patients. <i>Breast</i> , 2021, 59, 51-57.	0.9	13
20	Long-term outcome of patients with intermediate- and high-risk endometrial cancer after pelvic and paraaortic lymph node dissection: a comparison of laparoscopic vs. open procedure. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 961-969.	1.2	8
21	Risk of postmenopausal hormone therapy and patient history factors for the survival rate in women with endometrial carcinoma. <i>Archives of Gynecology and Obstetrics</i> , 2020, 301, 289-294.	0.8	5
22	HLA-G and HLA-F protein isoform expression in breast cancer patients receiving neoadjuvant treatment. <i>Scientific Reports</i> , 2020, 10, 15750.	1.6	15
23	Analysis of Oncological Second Opinions in a Certified University Breast and Gynecological Cancer Center in Relation to Complementary and Alternative Medicine. <i>Complementary Medicine Research</i> , 2020, 27, 431-439.	0.5	3
24	Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium. <i>British Journal of Cancer</i> , 2020, 123, 793-802.	2.9	35
25	Association of genomic variants at the human leukocyte antigen locus with cervical cancer risk, HPV status and gene expression levels. <i>International Journal of Cancer</i> , 2020, 147, 2458-2468.	2.3	12
26	Analysis of motives and patient satisfaction in oncological second opinions provided by a certified university breast and gynecological cancer center. <i>Archives of Gynecology and Obstetrics</i> , 2020, 301, 1299-1306.	0.8	6
27	Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 699-709.	5.1	104
28	A phase II single-arm, multicenter, open-label neoadjuvant study of pembrolizumab in combination with nab-paclitaxel followed by pembrolizumab in combination with epirubicin and cyclophosphamide in patients with triple-negative breast cancer: Neoimmunoboost.. <i>Journal of Clinical Oncology</i> , 2020, 38, e12647-e12647.	0.8	0
29	The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer. <i>Npj Breast Cancer</i> , 2019, 5, 38.	2.3	28
30	Two truncating variants in FANCC and breast cancer risk. <i>Scientific Reports</i> , 2019, 9, 12524.	1.6	5
31	Influence of patient and tumor characteristics on therapy persistence with letrozole in postmenopausal women with advanced breast cancer: results of the prospective observational EvAluate-TM study. <i>BMC Cancer</i> , 2019, 19, 611.	1.1	5
32	Preexisting musculoskeletal burden and its development under letrozole treatment in early breast cancer patients. <i>International Journal of Cancer</i> , 2019, 145, 2114-2121.	2.3	6
33	Prognostic effect of Ki-67 in common clinical subgroups of patients with HER2-negative, hormone receptor-positive early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019, 175, 617-625.	1.1	35
34	Genome-wide association study of germline variants and breast cancer-specific mortality. <i>British Journal of Cancer</i> , 2019, 120, 647-657.	2.9	52
35	Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. <i>American Journal of Human Genetics</i> , 2019, 104, 21-34.	2.6	711
36	Association between breast cancer risk factors and molecular type in postmenopausal patients with hormone receptor-positive early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019, 174, 453-461.	1.1	15

#	ARTICLE	IF	CITATIONS
37	Efficacy of neoadjuvant pertuzumab in addition to chemotherapy and trastuzumab in routine clinical treatment of patients with primary breast cancer: a multicentric analysis. <i>Breast Cancer Research and Treatment</i> , 2019, 173, 319-328.	1.1	40
38	Functional Analysis and Fine Mapping of the 9p22.2 Ovarian Cancer Susceptibility Locus. <i>Cancer Research</i> , 2019, 79, 467-481.	0.4	22
39	Associations of obesity and circulating insulin and glucose with breast cancer risk: a Mendelian randomization analysis. <i>International Journal of Epidemiology</i> , 2019, 48, 795-806.	0.9	81
40	TILGen: A Program to Investigate Immune Targets in Breast Cancer Patients - First Results on the Influence of Tumor-Infiltrating Lymphocytes. <i>Breast Care</i> , 2018, 13, 8-14.	0.8	32
41	Influence of side-effects on early therapy persistence with letrozole in post-menopausal patients with early breast cancer: Results of the prospective Evaluate-TM study. <i>European Journal of Cancer</i> , 2018, 96, 82-90.	1.3	36
42	Genetic overlap between endometriosis and endometrial cancer: evidence from cross-disease genetic correlation and GWAS meta-analyses. <i>Cancer Medicine</i> , 2018, 7, 1978-1987.	1.3	62
43	Dose adjustment of cisplatin, etoposide, and ifosfamide according to kidney function: a retrospective analysis and implications for medication safety. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2018, 391, 219-229.	1.4	3
44	BRCA mutations and their influence on pathological complete response and prognosis in a clinical cohort of neoadjuvantly treated breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2018, 171, 85-94.	1.1	56
45	Assessment of moderate coffee consumption and risk of epithelial ovarian cancer: a Mendelian randomization study. <i>International Journal of Epidemiology</i> , 2018, 47, 450-459.	0.9	15
46	Influence of patient and tumor characteristics on early therapy persistence with letrozole in postmenopausal women with early breast cancer: results of the prospective Evaluate-TM study with 3941 patients. <i>Annals of Oncology</i> , 2018, 29, 186-192.	0.6	35
47	A prediction model for pathological complete response after neoadjuvant chemotherapy of HER2-negative breast cancer patients. <i>Annals of Oncology</i> , 2018, 29, viii72.	0.6	0
48	Prediction of pathological complete response and prognosis in patients with neoadjuvant treatment for triple-negative breast cancer. <i>BMC Cancer</i> , 2018, 18, 1051.	1.1	59
49	Carboplatin/pegylated liposomal doxorubicin/bevacizumab (CD-BEV) vs. carboplatin/gemcitabine/bevacizumab (CG-BEV) in patients with recurrent ovarian cancer: A prospective randomized phase III ENGOT/GCIG-Intergroup study (AGO study group, AGO-Austria, Tj ETQq1 1 0.784314 rgBT / Overl	0.6	36
50	Pathway-Based Analysis of Genome-Wide Association Data Identified SNPs in HMMR as Biomarker for Chemotherapy- Induced Neutropenia in Breast Cancer Patients. <i>Frontiers in Pharmacology</i> , 2018, 9, 158.	1.6	21
51	Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility. <i>PLoS ONE</i> , 2018, 13, e0197561.	1.1	9
52	Identification of nine new susceptibility loci for endometrial cancer. <i>Nature Communications</i> , 2018, 9, 3166.	5.8	178
53	rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2473.	1.8	3
54	Using Probability for Pathological Complete Response (pCR) as a Decision Support Marker for Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer Patients – a Survey Among Physicians. <i>Geburtshilfe Und Frauenheilkunde</i> , 2018, 78, 707-714.	0.8	3

#	ARTICLE	IF	CITATIONS
55	Risk, Prediction and Prevention of Hereditary Breast Cancer – Large-Scale Genomic Studies in Times of Big and Smart Data. <i>Geburtshilfe Und Frauenheilkunde</i> , 2018, 78, 481-492.	0.8	38
56	A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer. <i>Nature Genetics</i> , 2018, 50, 968-978.	9.4	184
57	Dendritic cell vaccine (DCVAC) with chemotherapy (ct) in patients (pts) with recurrent epithelial ovarian carcinoma (EOC) after complete response (CR) to 1st-line platinum (Pt)-based ct: Primary analysis of a phase 2, open-label, randomized, multicenter trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, e17515-e17515.	0.8	4
58	Genetic risk factors for ovarian cancer and their role for endometriosis risk. <i>Gynecologic Oncology</i> , 2017, 145, 142-147.	0.6	24
59	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. <i>Nature Genetics</i> , 2017, 49, 680-691.	9.4	356
60	Association between mammographic density and pregnancies relative to age and BMI: a breast cancer case-only analysis. <i>Breast Cancer Research and Treatment</i> , 2017, 166, 701-708.	1.1	12
61	Dose-Response Association of CD8 ⁺ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer. <i>JAMA Oncology</i> , 2017, 3, e173290.	3.4	260
62	Association analysis identifies 65 new breast cancer risk loci. <i>Nature</i> , 2017, 551, 92-94.	13.7	1,099
63	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. <i>Nature Genetics</i> , 2017, 49, 1767-1778.	9.4	289
64	Genetic Breast Cancer Susceptibility Variants and Prognosis in the Prospectively Randomized SUCCESS A Study. <i>Geburtshilfe Und Frauenheilkunde</i> , 2017, 77, 651-659.	0.8	14
65	Predicting Triple-Negative Breast Cancer Subtype Using Multiple Single Nucleotide Polymorphisms for Breast Cancer Risk and Several Variable Selection Methods. <i>Geburtshilfe Und Frauenheilkunde</i> , 2017, 77, 667-678.	0.8	21
66	No Evidence That Genetic Variation in the Myeloid-Derived Suppressor Cell Pathway Influences Ovarian Cancer Survival. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 420-424.	1.1	3
67	Interest in Integrative Medicine Among Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM Study. <i>Integrative Cancer Therapies</i> , 2017, 16, 165-175.	0.8	22
68	Body mass index and breast cancer survival: a Mendelian randomization analysis. <i>International Journal of Epidemiology</i> , 2017, 46, 1814-1822.	0.9	45
69	Clinical validation of genetic variants associated with in vitro chemotherapy-related lymphoblastoid cell toxicity. <i>Oncotarget</i> , 2017, 8, 78133-78143.	0.8	6
70	Abstract P5-16-18: The effect of participation in neoadjuvant clinical trials on outcomes in patients with early breast cancer. , 2017, , .		0
71	<i>PALB2</i> , <i>CHEK2</i> and <i>ATM</i> rare variants and cancer risk: data from COGS. <i>Journal of Medical Genetics</i> , 2016, 53, 800-811.	1.5	174
72	Neoadjuvant Treatment of Breast Cancer - Advances and Limitations. <i>Breast Care</i> , 2016, 11, 313-314.	0.8	12

#	ARTICLE	IF	CITATIONS
73	The PI3K Pathway: Background and Treatment Approaches. <i>Breast Care</i> , 2016, 11, 398-404.	0.8	28
74	Factors Influencing Decision-Making for or against Adjuvant and Neoadjuvant Chemotherapy in Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM Study. <i>Breast Care</i> , 2016, 11, 315-322.	0.8	6
75	Assessing the genetic architecture of epithelial ovarian cancer histological subtypes. <i>Human Genetics</i> , 2016, 135, 741-756.	1.8	19
76	Five endometrial cancer risk loci identified through genome-wide association analysis. <i>Nature Genetics</i> , 2016, 48, 667-674.	9.4	77
77	A Review of Integrative Medicine in Gynaecological Oncology. <i>Geburtshilfe Und Frauenheilkunde</i> , 2016, 76, 150-155.	0.8	19
78	Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study. <i>International Journal of Epidemiology</i> , 2016, 45, 1619-1630.	0.9	111
79	Genetic Risk Score Mendelian Randomization Shows that Obesity Measured as Body Mass Index, but not Waist:Hip Ratio, Is Causal for Endometrial Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 1503-1510.	1.1	64
80	Chylous ascites after lymphadenectomy for gynecological malignancies. <i>Journal of Surgical Oncology</i> , 2016, 114, 613-618.	0.8	11
81	Computerized patient identification for the EMBRACA clinical trial using real-time data from the PRAEGNANT network for metastatic breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2016, 158, 59-65.	1.1	27
82	CYP19A1 fine-mapping and Mendelian randomization: estradiol is causal for endometrial cancer. <i>Endocrine-Related Cancer</i> , 2016, 23, 77-91.	1.6	62
83	Outcome and prognosis in uterine sarcoma and malignant mixed Mullerian tumor. <i>Archives of Gynecology and Obstetrics</i> , 2016, 294, 343-351.	0.8	21
84	Evidence of a genetic link between endometriosis and ovarian cancer. <i>Fertility and Sterility</i> , 2016, 105, 35-43.e10.	0.5	37
85	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. <i>Gynecologic Oncology</i> , 2016, 141, 386-401.	0.6	18
86	Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer. <i>Oncotarget</i> , 2016, 7, 69097-69110.	0.8	5
87	Germline polymorphisms in an enhancer of <i>PSIP1</i> are associated with progression-free survival in epithelial ovarian cancer. <i>Oncotarget</i> , 2016, 7, 6353-6368.	0.8	29
88	Abstract B32: Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses. <i>Cancer Research</i> , 2016, 76, B32-B32.	0.4	1
89	Meta-analysis of genome-wide association studies identifies common susceptibility polymorphisms for colorectal and endometrial cancer near SH2B3 and TSHZ1. <i>Scientific Reports</i> , 2015, 5, 17369.	1.6	35
90	Endometriosis as a risk factor for ovarian or endometrial cancer – results of a hospital-based case-control study. <i>BMC Cancer</i> , 2015, 15, 751.	1.1	25

#	ARTICLE	IF	CITATIONS
91	Epithelial-Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk. <i>Genetic Epidemiology</i> , 2015, 39, 689-697.	0.6	22
92	Common germline polymorphisms associated with breast cancer-specific survival. <i>Breast Cancer Research</i> , 2015, 17, 58.	2.2	26
93	Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQ into study. <i>International Journal of Cancer</i> , 2015, 137, 2981-2988.	2.3	31
94	Association of molecular subtypes with breast cancer risk factors. <i>European Journal of Cancer Prevention</i> , 2015, 24, 484-490.	0.6	14
95	Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk. <i>PLoS ONE</i> , 2015, 10, e0128106.	1.1	44
96	Cell-type-specific enrichment of risk-associated regulatory elements at ovarian cancer susceptibility loci. <i>Human Molecular Genetics</i> , 2015, 24, 3595-3607.	1.4	40
97	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. <i>Nature Genetics</i> , 2015, 47, 164-171.	9.4	221
98	Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. <i>Nature Genetics</i> , 2015, 47, 373-380.	9.4	513
99	Genome-wide significant risk associations for mucinous ovarian carcinoma. <i>Nature Genetics</i> , 2015, 47, 888-897.	9.4	78
100	Network-Based Integration of GWAS and Gene Expression Identifies a HOX-Centric Network Associated with Serous Ovarian Cancer Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 1574-1584.	1.1	28
101	Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium. <i>Clinical Cancer Research</i> , 2015, 21, 5264-5276.	3.2	33
102	Identification of Novel Genetic Markers of Breast Cancer Survival. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	3.0	56
103	Evaluating the ovarian cancer gonadotropin hypothesis: A candidate gene study. <i>Gynecologic Oncology</i> , 2015, 136, 542-548.	0.6	15
104	Candidate locus analysis of the TERT-CLPTM1L cancer risk region on chromosome 5p15 identifies multiple independent variants associated with endometrial cancer risk. <i>Human Genetics</i> , 2015, 134, 231-245.	1.8	34
105	Hormone Therapy and its Effect on the Prognosis in Breast Cancer Patients. <i>Geburtshilfe Und Frauenheilkunde</i> , 2015, 75, 588-596.	0.8	11
106	Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer. <i>Nature Communications</i> , 2015, 6, 8234.	5.8	63
107	Common variants at the CHEK2 gene locus and risk of epithelial ovarian cancer. <i>Carcinogenesis</i> , 2015, 36, 1341-1353.	1.3	24
108	Knowledge and attitudes regarding medical research studies among patients with breast cancer and gynecological diseases. <i>BMC Cancer</i> , 2015, 15, 587.	1.1	19

#	ARTICLE	IF	CITATIONS
109	Shared genetics underlying epidemiological association between endometriosis and ovarian cancer. <i>Human Molecular Genetics</i> , 2015, 24, 5955-5964.	1.4	68
110	Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses. <i>Cell</i> , 2015, 162, 974-986.	13.5	1,408
111	Comprehensive genetic assessment of the ESR1 locus identifies a risk region for endometrial cancer. <i>Endocrine-Related Cancer</i> , 2015, 22, 851-861.	1.6	25
112	Fine-mapping of the HNF1B multicancer locus identifies candidate variants that mediate endometrial cancer risk. <i>Human Molecular Genetics</i> , 2015, 24, 1478-1492.	1.4	50
113	Common Genetic Variation in Circadian Rhythm Genes and Risk of Epithelial Ovarian Cancer (EOC). <i>Journal of Genetics and Genome Research</i> , 2015, 2, .	0.3	25
114	Abstract 5488: Utilizing a pathway based analysis of genome wide association data to identify biomarkers of toxicity in breast cancer patients. , 2015, , .		0
115	Pooled analysis of the prognostic relevance of progesterone receptor status in five German cohort studies. <i>Breast Cancer Research and Treatment</i> , 2014, 148, 143-151.	1.1	45
116	Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study. <i>British Journal of Cancer</i> , 2014, 111, 2297-2307.	2.9	76
117	Expression of Neuroendocrine Markers in Different Molecular Subtypes of Breast Carcinoma. <i>BioMed Research International</i> , 2014, 2014, 1-9.	0.9	38
118	Variation in NF- κ B Signaling Pathways and Survival in Invasive Epithelial Ovarian Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 1421-1427.	1.1	13
119	Evaluation of Therapy Management and Patient Compliance in Postmenopausal Patients with Hormone Receptor-positive Breast Cancer Receiving Letrozole Treatment: The Evaluate TM Study. <i>Geburtshilfe Und Frauenheilkunde</i> , 2014, 74, 1137-1143.	0.8	11
120	Common non-synonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association Consortium. <i>Human Molecular Genetics</i> , 2014, 23, 6096-6111.	1.4	53
121	ABCA Transporter Gene Expression and Poor Outcome in Epithelial Ovarian Cancer. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	3.0	107
122	Risk of Ovarian Cancer and the NF- κ B Pathway: Genetic Association with <i>IL1A</i> and <i>TNFSF10</i> . <i>Cancer Research</i> , 2014, 74, 852-861.	0.4	48
123	Large-Scale Evaluation of Common Variation in Regulatory T Cell-Related Genes and Ovarian Cancer Outcome. <i>Cancer Immunology Research</i> , 2014, 2, 332-340.	1.6	21
124	Polymorphisms in the <i>RANK/RANKL</i> Genes and Their Effect on Bone Specific Prognosis in Breast Cancer Patients. <i>BioMed Research International</i> , 2014, 2014, 1-7.	0.9	18
125	Comprehensive visualization of paresthesia in breast cancer survivors. <i>Archives of Gynecology and Obstetrics</i> , 2014, 290, 135-141.	0.8	11
126	Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA. <i>Human Genetics</i> , 2014, 133, 481-497.	1.8	23

#	ARTICLE	IF	CITATIONS
127	Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer. <i>Carcinogenesis</i> , 2014, 35, 1012-1019.	1.3	145
128	Consortium analysis of gene and gene-folate interactions in purine and pyrimidine metabolism pathways with ovarian carcinoma risk. <i>Molecular Nutrition and Food Research</i> , 2014, 58, 2023-2035.	1.5	16
129	FGF receptor genes and breast cancer susceptibility: results from the Breast Cancer Association Consortium. <i>British Journal of Cancer</i> , 2014, 110, 1088-1100.	2.9	21
130	Response to "Screening depression during and after pregnancy using the EPDS". <i>Archives of Gynecology and Obstetrics</i> , 2014, 290, 603-603.	0.8	0
131	Socioeconomic status and depression during and after pregnancy in the Franconian Maternal Health Evaluation Studies (FRAMES). <i>Archives of Gynecology and Obstetrics</i> , 2014, 289, 755-763.	0.8	39
132	GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. <i>Nature Genetics</i> , 2013, 45, 362-370.	9.4	326
133	Shared decision-making in metastatic breast cancer: discrepancy between the expected prolongation of life and treatment efficacy between patients and physicians, and influencing factors. <i>Breast Cancer Research and Treatment</i> , 2013, 139, 429-440.	1.1	29
134	Prognostic relevance of Ki-67 in the primary tumor for survival after a diagnosis of distant metastasis. <i>Breast Cancer Research and Treatment</i> , 2013, 138, 899-908.	1.1	23
135	Breast Cancer Risk " From Genetics to Molecular Understanding of Pathogenesis. <i>Geburtshilfe Und Frauenheilkunde</i> , 2013, 73, 1228-1235.	0.8	33
136	Polymorphisms in Inflammation Pathway Genes and Endometrial Cancer Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 216-223.	1.1	22
137	Hormone replacement therapy and prognosis in ovarian cancer patients. <i>European Journal of Cancer Prevention</i> , 2013, 22, 52-58.	0.6	28
138	Mutation status of the mediator complex subunit 12 (MED12) in uterine leiomyomas and concurrent/metachronous multifocal peritoneal smooth muscle nodules (leiomyomatosis) Tj ETQq0 0 0 rgBT /Overlook 10 Tf 50 297 Td		
139	Amplified Cold Transduction in Native Nociceptors by M-Channel Inhibition. <i>Journal of Neuroscience</i> , 2013, 33, 16627-16641.	1.7	37
140	Analysis of Over 10,000 Cases Finds No Association between Previously Reported Candidate Polymorphisms and Ovarian Cancer Outcome. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 987-992.	1.1	20
141	The UGT1A6_19_GG genotype is a breast cancer risk factor. <i>Frontiers in Genetics</i> , 2013, 4, 104.	1.1	8
142	Percent Mammographic Density and Dense Area as Risk Factors for Breast Cancer. <i>Geburtshilfe Und Frauenheilkunde</i> , 2012, 72, 727-733.	0.8	31
143	Circulating Micro-RNAs as Potential Blood-Based Markers for Early Stage Breast Cancer Detection. <i>PLoS ONE</i> , 2012, 7, e29770.	1.1	219
144	Characterizing mammographic images by using generic texture features. <i>Breast Cancer Research</i> , 2012, 14, R59.	2.2	65

#	ARTICLE	IF	CITATIONS
145	Accuracy of radiological tumour size assessment and the risk for re-excision in a cohort of primary breast cancer patients. <i>European Journal of Surgical Oncology</i> , 2012, 38, 44-51.	0.5	26
146	Genome-Wide Association Study Identifies a Possible Susceptibility Locus for Endometrial Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 980-987.	1.1	32
147	Comparison of 6q25 Breast Cancer Hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC). <i>PLoS ONE</i> , 2012, 7, e42380.	1.1	51
148	Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. <i>Human Molecular Genetics</i> , 2011, 20, 3289-3303.	1.4	152
149	Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment. <i>BMC Cancer</i> , 2011, 11, 486.	1.1	260
150	Transient receptor potential cation channel, subfamily C, member 5 (TRPC5) is a cold-transducer in the peripheral nervous system. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 18114-18119.	3.3	192
151	Mammographic density as a risk factor for breast cancer in a German case-control study. <i>European Journal of Cancer Prevention</i> , 2011, 20, 1-8.	0.6	53
152	Genome-wide association study identifies a common variant associated with risk of endometrial cancer. <i>Nature Genetics</i> , 2011, 43, 451-454.	9.4	141
153	Diabetes and prognosis in a breast cancer cohort. <i>Journal of Cancer Research and Clinical Oncology</i> , 2011, 137, 975-983.	1.2	59
154	Breast Cancer Risk – Genes, Environment and Clinics. <i>Geburtshilfe Und Frauenheilkunde</i> , 2011, 71, 1056-1066.	0.8	55
155	Evaluation of variation in the phosphoinositide-3-kinase catalytic subunit alpha oncogene and breast cancer risk. <i>British Journal of Cancer</i> , 2011, 105, 1934-1939.	2.9	4
156	Estrogen Receptor Beta rs1271572 Polymorphism and Invasive Ovarian Carcinoma Risk: Pooled Analysis within the Ovarian Cancer Association Consortium. <i>PLoS ONE</i> , 2011, 6, e20703.	1.1	21
157	Assessment of mammographic density before and after first full-term pregnancy. <i>European Journal of Cancer Prevention</i> , 2010, 19, 405-412.	0.6	21
158	Breast cancer risk assessment in a mammography screening program and participation in the IBIS-II chemoprevention trial. <i>Breast Cancer Research and Treatment</i> , 2010, 121, 101-110.	1.1	26
159	Phenotyping sensory nerve endings in vitro in the mouse. <i>Nature Protocols</i> , 2009, 4, 174-196.	5.5	152
160	Morphological characterization of rat Mas-related G-protein-coupled receptor C and functional analysis of agonists. <i>Neuroscience</i> , 2008, 151, 242-254.	1.1	27